Compare Marsh & McLennan Companies, Inc. (MRSH) vs Novartis AG (NVS) Price & Performance

Marsh & McLennan Companies, Inc.Trade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Marsh & McLennan Companies, Inc. vs Novartis AG — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.6 (market cap $87.77B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3.3× Marsh & McLennan Companies, Inc.'s market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	MRSH	NVS
Market Cap	$87.77B	$290.25B
Sector	Financials	Health
52-Week High	$211.21	$168.62
52-Week Low	$157.32	$113.50
Enterprise Value	$108.61B	$330.27B
Dividend Yield	2.17%	3.17%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRSH

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 23 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About Marsh & McLennan Companies, Inc.

Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.